These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus. Rupp C; Hippchen T; Neuberger M; Sauer P; Pfeiffenberger J; Stremmel W; Gotthardt DN; Mehrabi A; Weiss KH World J Gastroenterol; 2018 Mar; 24(12):1353-1360. PubMed ID: 29599610 [TBL] [Abstract][Full Text] [Related]
4. Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study. Dalgard O; Weiland O; Noraberg G; Karlsen L; Heggelund L; Färkkilâ M; Balslev U; Belard E; Øvrehus A; Skalshøi Kjær M; Krarup H; Thorup Røge B; Hallager S; Madsen LG; Lund Laursen A; Lagging M; Weis N PLoS One; 2017; 12(7):e0179764. PubMed ID: 28704381 [TBL] [Abstract][Full Text] [Related]
5. Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience. Tsai WL; Wang CF; Cheng JS; Chen WC; Bair MJ; Lo CC PLoS One; 2020; 15(1):e0227424. PubMed ID: 31923251 [TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment. Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016 [TBL] [Abstract][Full Text] [Related]
7. Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand. Sirinawasatien A; Techasirioangkun T PLoS One; 2020; 15(2):e0229517. PubMed ID: 32106270 [TBL] [Abstract][Full Text] [Related]
8. Real-World Study on Sofosbuvir-based Therapies in Asian Americans With Chronic Hepatitis C. Pan CQ; Tiongson BC; Hu KQ; Han SB; Tong M; Chu D; Park J; Lee TP; Bhamidimarri KR; Ma X; Xiao PY; Mohanty SR; Wang D J Clin Gastroenterol; 2019 Feb; 53(2):147-154. PubMed ID: 29912759 [TBL] [Abstract][Full Text] [Related]
9. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia. Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Welzel TM; Nelson DR; Morelli G; Di Bisceglie A; Reddy RK; Kuo A; Lim JK; Darling J; Pockros P; Galati JS; Frazier LM; Alqahtani S; Sulkowski MS; Vainorius M; Akushevich L; Fried MW; Zeuzem S; Gut; 2017 Oct; 66(10):1844-1852. PubMed ID: 27418632 [TBL] [Abstract][Full Text] [Related]
11. Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection. Liu CH; Su TH; Liu CJ; Hong CM; Yang HC; Tseng TC; Chen PJ; Chen DS; Kao JH J Gastroenterol Hepatol; 2019 Sep; 34(9):1620-1625. PubMed ID: 30693965 [TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany. Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776 [TBL] [Abstract][Full Text] [Related]
13. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. Degasperi E; Spinetti A; Lombardi A; Landonio S; Rossi MC; Pasulo L; Pozzoni P; Giorgini A; Fabris P; Romano A; Lomonaco L; Puoti M; Vinci M; Gatti F; Carolo G; Zoncada A; Bonfanti P; Russo FP; Aghemo A; Soria A; Centenaro R; Maggiolo F; Rovere P; Pasin F; Paon V; Faggiano G; Vario A; Grossi G; Soffredini R; Carriero C; Paolucci S; Noventa F; Alberti A; Lampertico P; Fagiuoli S; J Hepatol; 2019 Dec; 71(6):1106-1115. PubMed ID: 31433303 [TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3. Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153 [TBL] [Abstract][Full Text] [Related]
16. Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study. Gayam V; Tiongson B; Khalid M; Mandal AK; Mukhtar O; Gill A; Garlapati P; Shrestha B; Khalid M; Chakraborty S; Guss D; Sherigar J; Mansour M; Mohanty S Eur J Gastroenterol Hepatol; 2018 Oct; 30(10):1200-1207. PubMed ID: 30096090 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience. Hlaing NKT; Mitrani RA; Aung ST; Phyo WW; Serper M; Kyaw AMM; Bwa AH; Win KM; Reddy KR J Viral Hepat; 2017 Nov; 24(11):927-935. PubMed ID: 28475232 [TBL] [Abstract][Full Text] [Related]
18. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study. Iqbal S; Yousuf MH; Yousaf MI World J Gastroenterol; 2017 Nov; 23(44):7899-7905. PubMed ID: 29209131 [TBL] [Abstract][Full Text] [Related]
19. High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar. Hlaing NKT; Nangia G; Tun KT; Lin S; Maung MZ; Myint KT; Kyaw AMM; Maung ST; Sein Win S; Bwa AH; Loza BL; Win KM; Reddy KR J Viral Hepat; 2019 Oct; 26(10):1186-1199. PubMed ID: 31104344 [TBL] [Abstract][Full Text] [Related]
20. Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens. Tayyab GUN; Rasool S; Nasir B; Rubi G; Abou-Samra AB; Butt AA BMC Gastroenterol; 2020 Apr; 20(1):93. PubMed ID: 32252635 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]